Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | PALB2 del exon11 |
Therapy | Olaparib |
Indication/Tumor Type | endometrial serous adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PALB2 del exon11 | endometrial serous adenocarcinoma | predicted - sensitive | Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) treatment resulted in a durable response lasting 23 months in a patient with recurrent serous endometrial carcinoma harboring a germline deletion of PALB2 exon 11 (PMID: 34781271). | 34781271 |
PubMed Id | Reference Title | Details |
---|---|---|
(34781271) | Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer. | Full reference... |